The Complexity and Challenges of Developing Effective Epilepsy Therapies: Lessons to be Learned from Comparing Cenobamate, Carisbamate, and Padsevonil.

Overall, 29/149 (19.5%) patients responded with ≥75% seizure suppression in the non-SV2A group compared with 14/175 (8%) patients in the SV2A group, a highly significant difference ( P = 0.0020; Fisher’s exact test).

also in 132,142 other papers

7 , this primary outcome did not reach statistical significance compared with placebo.

also in 111,027 other papers

Both trials failed to reach statistical significance for any padsevonil dose group compared with placebo [ 14 ].

also in 6,035 other papers